Granules India Limited (GRANULES) share price and analysis
GRANULES last traded at ₹797.50 (-2.21%) on the NSE. Market cap ₹21,754 Cr (Small cap), Pharma & Healthcare sector.
Overall rating: 7.5/10 (Good)
- Valuation: 8.3/10
- Profitability: 6.1/10
- Growth: 10.0/10
- Financial health: 6.0/10
- Price trend: 7.3/10
Long-term view: Strong long-term candidate. Business quality and valuation clearly outweigh the weaknesses. Trade bias (next few weeks): Strong long. Trend and momentum are clearly pointing up.
Strengths of GRANULES
- Valuation (P/E) (P/E 27.9 vs sector 41.3): Trades about 32% below its sector's median P/E, so it's cheaper than peers. Make sure growth isn't the reason.
- Long-term trend (+6.0% vs 200-DMA): Trading well above its 200-day average, a clear long-term uptrend.
- Revenue growth (YoY) (+20.3%): Sales are growing fast.
- Profit growth (YoY) (+30.7%): Profits are growing rapidly.
- 50-DMA vs 200-DMA (+10.9% gap): 50-day average is above the 200-day (golden-cross setup), so medium-term momentum is up.
- Debt / equity (0.17): Comfortable debt level.
- Net profit margin (12.1%): Healthy profit margins.
- Current ratio (2.60): Plenty of short-term assets to cover short-term bills.
- Price vs growth (PEG) (PEG 0.91): Reasonable price for its growth rate.
- Analyst target (₹903 (+13.3%)): 8 analysts' average target implies +13.3%, moderate upside.
- 52-week range (14% below high): In the upper half of its 52-week range.
Weaknesses of GRANULES
- Free cash flow (Negative): Burning cash, because free cash flow is negative. Growth is being funded by debt, equity or reserves.
- Momentum (RSI 14) (RSI 45): Momentum is soft.
Key numbers
| Number | Value | Assessment | Normal range |
|---|---|---|---|
| P/E (TTM) | 27.9 | Cheaper than peers | 37.2–49.5 (sector median 41.3) |
| Forward P/E | 21.0 | Profits expected to grow | below today's P/E (27.9) and near 41 |
| Price / book | 3.06 | Normal | 2–6 |
| EPS (TTM) | ₹28.57 | Profitable | above ₹0 |
| Return on equity | 13.5% | Average | 15%+ (below 10% is weak) |
| Debt / equity | 0.17 | Low debt | below 1.0 (under 0.5 is great) |
| Net margin | 12.1% | Healthy | 10%+ (below 5% is thin) |
| Operating margin | 17.3% | Average | 20%+ strong, below 10% thin |
| Revenue growth | +20.3% | Growing well | 10%+ a year (below 3% is weak) |
| Profit growth | +30.7% | Growing well | 10%+ a year (falling is weak) |
| Dividend yield | 0.21% | Small payout | 1.5%+ (none is fine for growth firms) |
| Current ratio | 2.60 | Comfortable | 1.5+ (below 1 is tight) |
| 52W high | ₹923.65 | 14% below · near the high | price in the top 40% of its 52-week range |
| 52W low | ₹529.85 | Price is 51% above it | |
| 50-DMA | ₹834.49 | Price 4.4% below | price above it = short-term uptrend |
| 200-DMA | ₹752.33 | Price 6.0% above | price above it = long-term uptrend |
| 1Y return | +45.0% | Beat the Nifty 50 | Nifty 50 did −1.4% |
| Beta | 0.12 | Steadier than the market | 0.8–1.3 (1 = moves with market) |
| Promoter / insider | 39.6% | Moderate stake | 50%+ shows owner commitment |
| Institutions | 23.0% | Moderate interest | 30%+ is strong |
| Analyst target | ₹903.25 | 13.3% upside · 8 analysts | 8%+ upside |
Questions about GRANULES
What is the share price of Granules India Limited (GRANULES) today?
GRANULES last traded at ₹797.50 (-2.21% on the day) on the NSE. Its 52-week range is ₹529.85 to ₹923.65. Prices are delayed and come from Yahoo Finance.
Is GRANULES a good stock for the long term?
StockLens rates GRANULES 7.5 out of 10 (Good) overall. Its long-term verdict is "Strong long-term candidate": Business quality and valuation clearly outweigh the weaknesses. Strengths: cheap vs peers, uptrend, revenue growth. Concerns: cash burn, soft momentum.
Is GRANULES share overvalued?
GRANULES trades at a P/E of 27.9 against a Pharma & Healthcare median of 41.3, which StockLens rates as "Cheaper than peers". Its price-to-book ratio is 3.06.
Is GRANULES good for short-term trading?
The trade bias for the next few weeks is "Strong long": Trend and momentum are clearly pointing up. The price is 6.0% above its 200-day average and 14-day RSI is 45.
Which stocks are similar to GRANULES?
Similar Pharma & Healthcare stocks of comparable size include Natco Pharma, Biocon, Alkem Laboratories, Glenmark Pharmaceuticals, Lupin. You can compare up to 4 of them side by side on StockLens.
About Granules India Limited
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Stocks similar to GRANULES
- Natco Pharma share price
- Biocon share price
- Alkem Laboratories share price
- Glenmark Pharmaceuticals share price
- Lupin share price
- Max Healthcare share price
Compare GRANULES with NATCOPHARM, BIOCON, ALKEM
Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.